Press Release: November 11, 2020
Webinar Date: Tuesday, 8th December 2020, 11:00am EST / 8:00am PST
The small molecule program was started with the aim to identify lead series and lead compounds for the inhibition of NNMT to treat metabolic disorders. The project team faced numerous challenges during the program such as a moderate ADME profile of the starting compounds, establishing biochemical assays for the target and several selectivity assays, establishing target engagement and efficacy models, and such. In this webinar, we will be discussing the strategic workflows to overcome such challenges, our project journey, and the swift successful delivery of a lead series and lead compounds.
Our 4D focused project approach, attributed premier importance to scientific value addition, driving scientific insights about the metabolic therapeutic domain – pharmacological benefits in vivo. In addition, we offer a platform for all the attendants to share their best practices, experiences, and bring in their queries.
· Overcoming Hit to Lead challenges
· Deciding on the best approach
· Fast-tracking Milestone achievement
Dr. Takeshi Yura
Vice President – Medicinal Chemistry
Dr. Yura has more than 28 years' experience in Medicinal and Organic Chemistry, beginning his career with Tanabe Seiyaku Tokyo Research Center where he worked as Research Chemist. Post this he was associated with Ciba Geigy Japan (Takarazuka Research Center), Bayer Yakuhin (Research Center Kyoto), Pfizer Japan (Pfizer Global Research and Development Nagoya Laboratories), and Dishman Japan Ltd.
Before joining Jubilant Biosys, Dr. Yura worked with Albany Molecular Research Singapore Research Centre, Pte. Ltd, as Vice President, Discovery and Development Services for Asia and General Manager for Singapore Research Centre. At AMRI he was responsible for, AMRI Singapore Research Centre's chemistry and biology operations and AMRI Hyderabad Research Centre.
Dr. Yura was awarded a Ph.D. degree in Chemistry from the University of Tokyo, Japan. He has completed his Executive MBA program at Temple University, Tokyo, Japan.
About Jubilant Biosys Limited:
Jubilant Biosys is a leading contract research organization that offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry, PR&D, and GMP scale-up capabilities up to phase II. It has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS, and expanding into Rare Diseases.
For more info, please visit: https://www.jubilantbiosys.com/advancing-small-molecule-program-from-hit-to-candidate/